Alcon Diclofenac Label Change Planned Following AE Reports
Executive Summary
Alcon has initiated discussions with FDA to develop new class labeling that better addresses adverse events associated with ophthalmic NSAID use, the company announced following its Aug. 20 suspension of distribution of diclofenac sodium ophthalmic solution due to reports of serious corneal adverse events.
You may also be interested in...
Alcon Provides Documents In Philadelphia PBM Investigation
PBM switch campaigns for ophthalmic drugs may be an area of interest in the federal investigation of pharmaceutical benefit management practices.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011